FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President and CEO: Masahiro Morimoto, hereinafter referred to as FRONTEO) has announced the exclusive development and sale of an AI program that supports the diagnosis of depression at Keio University School of Medicine (location: Shinjuku, Tokyo). We have reached an agreement with the District.

　FRONTEO and Keio University School of Medicine have been conducting joint research since 2015 on an AI program that supports diagnosis of depression, manic depression, and dementia using conversations between medical professionals and patients. In 2020, we concluded a license agreement for exclusive development and sales rights for a dementia diagnosis support AI program.¹⁾We are proceeding with the development of this program for practical use.With this agreement, we will also move forward with efforts to commercialize and commercialize the depression diagnosis support AI program.

[Source] Created by FRONTEO from the Ministry of Health, Labor and Welfare's "Patient Survey"

　According to the Ministry of Health, Labor and Welfare's "Patient Survey," the number of patients with mood [emotional] disorders has approximately tripled from 1996 to 2017.²⁾, mental health measures have become an important issue. FRONTEO will strive to help solve this issue through the development and social implementation of AI technology.

1) FRONTEO agrees with Keio University School of Medicine on a license for commercialization of a dementia diagnosis support system using AI, https://www.fronteo.com/20200701
2) Ministry of Health, Labor and Welfare: Patient survey, https://www.mhlw.go.jp/stf/wp/hakusyo/kousei/18/backdata/01-01-02-09.html

■Special notes
This research and development is a medical device and system research and development project to realize future medical care of the Japan Agency for Medical Research and Development (AMED), a national research and development agency. This was done with the support of "Development of a device that delivers

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

* FRONTEO and KIBIT are registered trademarks of FRONTEO in Japan.